CN105521100A - Traditional Chinese medicinal composition for treating leucopenia after chemotherapy - Google Patents

Traditional Chinese medicinal composition for treating leucopenia after chemotherapy Download PDF

Info

Publication number
CN105521100A
CN105521100A CN201610049644.9A CN201610049644A CN105521100A CN 105521100 A CN105521100 A CN 105521100A CN 201610049644 A CN201610049644 A CN 201610049644A CN 105521100 A CN105521100 A CN 105521100A
Authority
CN
China
Prior art keywords
parts
chemotherapy
traditional chinese
chinese medicinal
medicinal composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610049644.9A
Other languages
Chinese (zh)
Inventor
刘学键
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Huazhicao Medical Technology Co Ltd
Original Assignee
Qingdao Huazhicao Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Huazhicao Medical Technology Co Ltd filed Critical Qingdao Huazhicao Medical Technology Co Ltd
Priority to CN201610049644.9A priority Critical patent/CN105521100A/en
Publication of CN105521100A publication Critical patent/CN105521100A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/57Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/074Ganoderma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • A61K36/344Codonopsis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/487Psoralea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/732Chaenomeles, e.g. flowering quince
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon

Abstract

The invention discloses a traditional Chinese medicinal composition for treating leucopenia after chemotherapy, belonging to the technical field of traditional Chinese medicines. The traditional Chinese medicinal composition is prepared from the following traditional Chinese medicinal materials: radix astragali, radix codonopsis, donkey-hide gelatin, lucid ganoderma, ternate buttercup root, Chinese lobelia herb, fructus psoraleae, fructus chaenomelis, poria cocos, endothelium corneum gigeriae galli and fruits of immature citron. The traditional Chinese medicinal composition is obtained on the basis of the ancestral prescriptions for supporting the healthy energy and through the long-term improvement, has a leukogenic function, can improve the immune function and the disease resistance of the organism, and also can reduce the harm of chemotherapy to the organism, so that the smooth conduction of chemotherapy is guaranteed, the life quality of patients is improved to a great extent, the lifetime of the patients is prolonged, and the traditional Chinese medicinal composition is suitable for clinic application.

Description

A kind of Chinese medicine composition for the treatment of leukopenia after chemotherapy
Technical field
The invention belongs to technical field of Chinese medicines, particularly a kind of Chinese medicine composition for the treatment of leukopenia after chemotherapy.
Background technology
Chemotherapy, radiotherapy are one of main method of Therapeutic cancer, and chemotherapy is the abbreviation of chemotherapy, are to utilize chemicals to stop the propagation of cancerous cell, infiltration, transfer, until finally kill a kind of therapeutic modality of cancerous cell.Because the selectivity of chemotherapeutics is not strong, while killing cancerous cell, also inevitably can damages the cell of human normal, thus occur the untoward reaction of medicine.And modal dose-limiting toxicity is bone marrow depression, shows as total white blood cells, neutrophilic granulocyte absolute value and (or) thrombocytopenia, therefore have impact on the effect for the treatment of of cancer.
Therefore, protection hemopoietic function of bone marrow, increases leukocyte count, and reduction chemotherapy and the damage of carcinous toxin to hemopoietic system seem particularly important.Leukopenia refers to that patient peripheral's total white blood cells continues lower than 4 × 10/L.Treat the leukopenia many employings colony stimulating factor caused by chemotherapeutics in recent years and carry out auxiliary treatment, this type of curative effect of medication is remarkable but price comparison is expensive.Still have other therapies in addition as hormonotherapy, shortcoming is that curative effect is unreliable and easily bring out infection; Oral vitamin, batilol, leucogen, although there is certain leukocyte increasing effect, costly, be easy to repeatedly, unsatisfactory curative effect.
Summary of the invention
The present invention is on the basis of strengthening the body resistance prescription handed down from one's ancestors, and through long-term improvement, provide a kind of Chinese medicine composition for the treatment of the leukopenia that chemotherapy causes, it has the effect of leukocyte increasing.Chinese medicine composition of the present invention both can improve body's immunity and resistance against diseases, can reduce again the injury of chemotherapy to body, thus ensure that completing smoothly of chemotherapy, improve the life quality of patient to a great extent, extended the survival of patients phase.
For solving the problem, the technical solution adopted in the present invention is:
Treat a Chinese medicine composition for leukopenia after chemotherapy, be prepared from by following Chinese herb: the Radix Astragali, Radix Codonopsis, Colla Corii Asini, Ganoderma, Radix Ranunculi Ternati, Herba Lobeliae Chinensis, Fructus Psoraleae, Fructus Chaenomelis, Poria, Endothelium Corneum Gigeriae Galli, Fructus Aurantii Immaturus.
Preferably, the Chinese medicine composition that the present invention treats leukopenia after chemotherapy is prepared from by the Chinese herb of following weight portion: Radix Astragali 8-28 part, Radix Codonopsis 8-28 part, Colla Corii Asini 1-6 part, Ganoderma 1-6 part, Radix Ranunculi Ternati 8-28 part, Herba Lobeliae Chinensis 1-6 part, Fructus Psoraleae 3-12 part, Fructus Chaenomelis 4-16 part, Poria 4-16 part, Endothelium Corneum Gigeriae Galli 4-16 part, Fructus Aurantii Immaturus 4-16 part.
Optimize two schemes with better curative effect further:
Prescription 1: the Radix Astragali 24 parts, Radix Codonopsis 24 parts, 3 parts, Colla Corii Asini, Ganoderma 3 parts, Radix Ranunculi Ternati 15 parts, Herba Lobeliae Chinensis 3 parts, Fructus Psoraleae 6 parts, Fructus Chaenomelis 12 parts, 12 parts, Poria, Endothelium Corneum Gigeriae Galli 6 parts, Fructus Aurantii Immaturus 12 parts.
Prescription 2: the Radix Astragali 20 parts, Radix Codonopsis 20 parts, 5 parts, Colla Corii Asini, Ganoderma 4 parts, Radix Ranunculi Ternati 20 parts, Herba Lobeliae Chinensis 4 parts, Fructus Psoraleae 3 parts, Fructus Chaenomelis 8 parts, 8 parts, Poria, Endothelium Corneum Gigeriae Galli 10 parts, Fructus Aurantii Immaturus 10 parts.
The present invention also provides a kind of method preparing above-mentioned Chinese medicine composition, concrete steps are: take the Radix Astragali, Radix Codonopsis, Colla Corii Asini, Ganoderma, Radix Ranunculi Ternati, Herba Lobeliae Chinensis, Fructus Psoraleae, Fructus Chaenomelis, Poria, Endothelium Corneum Gigeriae Galli, each taste raw material of Fructus Aurantii Immaturus respectively according to Chinese prescription, add the water extraction 2 times of above-mentioned raw material gross weight 8-10 times amount, each 1-2h, merge extractive liquid, concentrating under reduced pressure obtains thick paste, by thick paste drying and crushing, to obtain final product.
The Chinese medicine composition that the present invention treats leukopenia after chemotherapy conventionally can add appropriate amount of auxiliary materials, is prepared into conventional pharmaceutical formulation, such as capsule, tablet, decoction, powder, pill, granule etc.
Wherein:
The Radix Astragali: [nature and flavor] are sweet, temperature.[return through] returns lung, spleen channel.[function cures mainly] invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.Weak for the deficiency of vital energy, anorexia and loose stool, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, deficiency of vital energy edema, carbuncle difficulty is burst, and burst for a long time and do not hold back, blood deficiency dull yellowish colored skin, interior-heat is quenched one's thirst; Chronic nephritis proteinuria, diabetes.
Radix Codonopsis: [nature and flavor] are sweet is flat.[return through] returns spleen, lung meridian.[function cures mainly] invigorating the spleen and replenishing QI, spleen invigorating lung benefiting.For deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency is coughed, and interior-heat is quenched one's thirst.
Colla Corii Asini: [nature and flavor] are sweet is flat.[return through] returns spleen, lung meridian.[function cures mainly] invigorating the spleen and replenishing QI, spleen invigorating lung benefiting.For deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency is coughed, and interior-heat is quenched one's thirst.
Ganoderma: [nature and flavor] are sweet, flat.[return through] GUIXIN, lung, liver, kidney channel.[function cures mainly] invigorating QI and tranquilization, relieving cough and asthma.For dizzy sleeplessness, shortness of breath and palpitation, asthenia cough with asthma.
Radix Ranunculi Ternati: [nature and flavor] sweet, acrid, warm.[return through] returns liver, lung meridian.[function cures mainly] eliminating stagnation, detumescence., tuberculous lymphadenitis not routed for scrofula.
Herba Lobeliae Chinensis: [nature and flavor] are pungent, flat.[return through] GUIXIN, small intestinal, lung meridian.[function cures mainly] inducing diuresis to remove edema, heat-clearing and toxic substances removing.For extensive abdominal edema, face foot edema, carbuncle furuncle, snake bite and insect sting; Advanced schistosomiasis ascites.
Fructus Psoraleae: [nature and flavor] are pungent, bitter, temperature.[return through] returns kidney, spleen channel.[function cures mainly] kidney invigorating and YANG supporting, Gu through reducing urination, warming spleen and stopping diarrha, helping inspiration to relieve asthma.
Fructus Chaenomelis: [nature and flavor] acid, temperature.[return through] returns liver, spleen channel.[function cures mainly] suppressing the hyperactive liver relaxing muscles and tendons, stomach function regulating removing dampness.For arthralgia chiefly caused by damp pathogen contracture, the heavy pain of waist knee joint acid, convulsion of vomiting and diarrhoea, beriberi edema.
Poria: [nature and flavor] are sweet, light is flat.[return through] GUIXIN, lung, spleen, kidney channel.[function cures mainly] promoting diuresis to eliminate damp pathogen, spleen invigorating mind calming.For edema oliguria, phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, have loose bowels in loose stool, irritability, palpitation with fear insomnia.
Endothelium Corneum Gigeriae Galli: [nature and flavor] are sweet is flat.[return through] returns spleen, stomach, small intestinal, urinary bladder channel.[function cures mainly] invigorating the stomach and promoting digestion, arresting seminal emission.Do not disappear for food stagnation, vomiting dysentery, infantile malnutrition, the enuresis, seminal emission.
Fructus Aurantii Immaturus: [nature and flavor] are bitter, pungent, sour, temperature.[return through] returns spleen, stomach warp.[function cures mainly] dispelling the stagnated QI removing food stagnancy, loose painful abdominal mass of reducing phlegm.Stop in stagnant, feeling of fullness distending pain, heavy after dysentery, constipation, the stagnant vapour lock thoracic obstruction of expectorant, blocked-up chest; Gastroptosis, proctoptosis, uterine prolapse.
Combinationally use through the above-mentioned Chinese crude drug of clinical verification, can interact, Synergistic, there is stimulation Leukocytopoiesis, increase quantity of leucocyte, repair hemopoietic system, make the effect that neutrophilic granulocyte increases, thoroughly can remove the symptoms such as headache that the leukopenia that causes because of chemotherapy brings, low grade fever, weak, general malaise, pharyngeal infection.
Good effect of the present invention, raw material is easy to get green natural, and clinical experiment confirms that it has and shortens numeration of leukocyte recovery time, increases leukocytic effect.Therefore, the present invention's also application of claimed above-mentioned Chinese medicine composition in the medicine of preparation treatment leukopenia after chemotherapy.
Detailed description of the invention
Further describe the present invention below in conjunction with specific embodiment, but be not limited only to following specific embodiment.
embodiment 1the preparation of Chinese medicinal composition capsules agent of the present invention
Take the Radix Astragali 24 parts, Radix Codonopsis 24 parts, 3 parts, Colla Corii Asini, Ganoderma 3 parts, Radix Ranunculi Ternati 15 parts, Herba Lobeliae Chinensis 3 parts, Fructus Psoraleae 6 parts, Fructus Chaenomelis 12 parts, 12 parts, Poria, Endothelium Corneum Gigeriae Galli 6 parts, Fructus Aurantii Immaturus 12 parts respectively; Add the water extraction 2 times of above-mentioned raw material gross weight 9 times amount, each 2h, merge extractive liquid, concentrating under reduced pressure obtains thick paste, by thick paste drying and crushing, adds appropriate amount of auxiliary materials mixing, incapsulates, make every capsules containing crude drug 0.5g.
embodiment 2the preparation of Chinese medicinal composition capsules agent of the present invention
Take the Radix Astragali 20 parts, Radix Codonopsis 20 parts, 5 parts, Colla Corii Asini, Ganoderma 4 parts, Radix Ranunculi Ternati 20 parts, Herba Lobeliae Chinensis 4 parts, Fructus Psoraleae 3 parts, Fructus Chaenomelis 8 parts, 8 parts, Poria, Endothelium Corneum Gigeriae Galli 10 parts, Fructus Aurantii Immaturus 10 parts respectively; Add the water extraction 2 times of above-mentioned raw material gross weight 9 times amount, each 2h, merge extractive liquid, concentrating under reduced pressure obtains thick paste, by thick paste drying and crushing, adds appropriate amount of auxiliary materials mixing, incapsulates, make every capsules containing crude drug 0.5g.
embodiment 3the preparation of Chinese medicinal composition capsules agent of the present invention
Take the Radix Astragali 8 parts, Radix Codonopsis 8 parts, 1 part, Colla Corii Asini, Ganoderma 1 part, Radix Ranunculi Ternati 8 parts, Herba Lobeliae Chinensis 1 part, Fructus Psoraleae 3 parts, Fructus Chaenomelis 4 parts, 4 parts, Poria, Endothelium Corneum Gigeriae Galli 4 parts, Fructus Aurantii Immaturus 4 parts respectively; Add the water extraction 2 times of above-mentioned raw material gross weight 9 times amount, each 2h, merge extractive liquid, concentrating under reduced pressure obtains thick paste, by thick paste drying and crushing, adds appropriate amount of auxiliary materials mixing, incapsulates, make every capsules containing crude drug 0.5g.
embodiment 4the preparation of Chinese medicinal composition capsules agent of the present invention
Take the Radix Astragali 28 parts, Radix Codonopsis 28 parts, 6 parts, Colla Corii Asini, Ganoderma 6 parts, Radix Ranunculi Ternati 28 parts, Herba Lobeliae Chinensis 6 parts, Fructus Psoraleae 12 parts, Fructus Chaenomelis 16 parts, 16 parts, Poria, Endothelium Corneum Gigeriae Galli 16 parts, Fructus Aurantii Immaturus 16 parts respectively; Add the water extraction 2 times of above-mentioned raw material gross weight 9 times amount, each 2h, merge extractive liquid, concentrating under reduced pressure obtains thick paste, by thick paste drying and crushing, adds appropriate amount of auxiliary materials mixing, incapsulates, make every capsules containing crude drug 0.5g.
embodiment 5 clinical data
1. data and method:
1.1 object
The patient 306 routine patients undergoing chemotherapy of case source for being selected from August, 2013 to 2015 year diagnosis and treatment in August, all be diagnosed as malignant tumor through cytology or histopathology, and KarnofskyShi standards of grading are more than 50 points, after chemotherapy, confirm that total white blood cells continues lower than 4 × 10 through looking into surrounding hemogram 9/ L, estimates to complete the patient that whole-course treatment also agrees to accept chemotherapy.(side by side except following patient: chemotherapeutic period applies other any shengbai drug persons; Merge severe cardiac, liver, kidney, disease in the blood system patient; Infected patient and gestational patients; There are medicine and food anaphylaxis history person.) adopt neat same contrast, directly matched pairs procedure, patient is matched by sex, mean age (age gap is less than 3 years old), sick kinds, pain degree, karnofsky scoring, then is divided into treatment 1 group at random, treats 2 groups and matched group, often organize each 102 routine, treat 1 group: man 56 example, female 46 example; 52.8 years old mean age; Treat 2 groups: man 54 example, female 48 example; 53.2 years old mean age; Matched group: man 55 example, female 47 example; 53.0 years old mean age; Three groups of Gender, mean age, sick kind, pain degree, karnofsky scoring etc. contrast there was no significant differences, have harmony.
1.2 leukocyte calibration
WBC calibration standard according to the World Health Organization (WHO) specifies:
0 degree: WBC counting is not less than 4.0 × 10 9/ L, WBC do not reduce;
I degree: WBC counts 3.0 × 10 9-3.9 × 10 9/ L, slightly reduces;
II degree: WBC counts 2.0 × 10 9-2.9 × 10 9/ L, moderate reduces;
degree: WBC counting 1.0 × 10 9-1.9 × 10 9/ L, severe reduces;
IV degree: WBC counts lower than 1.0 × 10 9/ L, only a few patient entail dangers to life.
1.3 Therapeutic Method
Treat 1 group: give capsule prepared by the embodiment of the present invention 1.Oral from after end of chemotherapy 24h, every day 3 times, each 3-4 grain.The course for the treatment of is 14d;
Treat 2 groups: give capsule prepared by the embodiment of the present invention 2.Oral from after end of chemotherapy 24h, every day 3 times, each 3-4 grain.The course for the treatment of is 14d;
Matched group: application Batilol tablet (taking 3 times/d, 50mg/ time) and leucogen's sheet (taking 3 times/d, 20mg/ time) treatment, the course for the treatment of is 14d.
Three groups of patient's same disease and identical histological type person select identical chemotherapy regimen, and conventional anti symptom treatment, viewing duration is not transfused blood, without the medicine of other influences peripheral white blood cell.All extract patient's empty stomach ulnar vein blood with conventional sense WBC counting early morning before and after treatment, compare two groups of patient WBC situations of change.
1.4 statistical analysis
Data acquisition SPSS19.0 software carries out statistical analysis, measurement data with represent, before and after treatment, Indexes Comparison adopts t inspection; Enumeration data adopts X 2inspection, touchstone α=0.05, P < 0.05 represents that difference has statistical significance.
2 experimental results
WBC change in count before and after 2.1 treatment groups and treatment of control group
WBC change in count before and after table 1 treatment group and treatment of control group ( , 10 9/ L)
Note: with this group before treatment, *p < 0.05.
The WBC count ratio for the treatment of first three groups patient comparatively, there is not statistical significance (P > 0.05) in difference, after treatment, comparatively, there is not statistical significance (P > 0.05) in difference to the WBC count ratio of three groups of patients, but treatment group effect is slightly better than matched group; Visible after treatment, obviously rising before three groups of patient WBC count all comparatively treatment, all there is statistical significance (P < 0.05) in difference.
Treatment group and matched group WBC calibration situation after 2.2 treatments
Table 2 treats rear matched group and observation group WBC calibration situation [n(%)]
Note: compare with matched group, *p < 0.05.
Treat 1 group of WBC counting to reach normal person and account for 80.4%, treat 2 groups of WBC countings and reach normal person and account for 78.4%, matched group WBC counting reaches normal person and accounts for 58.9%, and three groups are compared, and difference exists statistical significance (P < 0.05).
5.3 untoward reaction
Treat 1 group, treat 2 groups: do not occur any untoward reaction.
Matched group: the symptoms such as malaise, headache, dizziness, inappetence, nausea and vomiting appear in 70 routine patients.
Above experimental data proved invention Chinese medicine composition can reduce the incidence rate of leukopenia after Chemotherapy of Tumor Patients, and curative effect is better than clinically conventionally rising WBC medicine, easy and simple to handle, price is lower, is worthy of popularization.

Claims (3)

1. treat a Chinese medicine composition for leukopenia after chemotherapy, it is characterized in that, be prepared from by following Chinese herb: the Radix Astragali, Radix Codonopsis, Colla Corii Asini, Ganoderma, Radix Ranunculi Ternati, Herba Lobeliae Chinensis, Fructus Psoraleae, Fructus Chaenomelis, Poria, Endothelium Corneum Gigeriae Galli, Fructus Aurantii Immaturus.
2. the Chinese medicine composition for the treatment of leukopenia after chemotherapy according to claim 1, it is characterized in that, be prepared from by the Chinese herb of following weight portion: Radix Astragali 8-28 part, Radix Codonopsis 8-28 part, Colla Corii Asini 1-6 part, Ganoderma 1-6 part, Radix Ranunculi Ternati 8-28 part, Herba Lobeliae Chinensis 1-6 part, Fructus Psoraleae 3-12 part, Fructus Chaenomelis 4-16 part, Poria 4-16 part, Endothelium Corneum Gigeriae Galli 4-16 part, Fructus Aurantii Immaturus 4-16 part.
3. the Chinese medicine composition for the treatment of leukopenia after chemotherapy according to claim 2, it is characterized in that, be prepared from by the Chinese herb of following weight portion: the Radix Astragali 24 parts, Radix Codonopsis 24 parts, 3 parts, Colla Corii Asini, Ganoderma 3 parts, Radix Ranunculi Ternati 15 parts, Herba Lobeliae Chinensis 3 parts, Fructus Psoraleae 6 parts, Fructus Chaenomelis 12 parts, 12 parts, Poria, Endothelium Corneum Gigeriae Galli 6 parts, Fructus Aurantii Immaturus 12 parts.
CN201610049644.9A 2016-01-26 2016-01-26 Traditional Chinese medicinal composition for treating leucopenia after chemotherapy Withdrawn CN105521100A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610049644.9A CN105521100A (en) 2016-01-26 2016-01-26 Traditional Chinese medicinal composition for treating leucopenia after chemotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610049644.9A CN105521100A (en) 2016-01-26 2016-01-26 Traditional Chinese medicinal composition for treating leucopenia after chemotherapy

Publications (1)

Publication Number Publication Date
CN105521100A true CN105521100A (en) 2016-04-27

Family

ID=55763846

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610049644.9A Withdrawn CN105521100A (en) 2016-01-26 2016-01-26 Traditional Chinese medicinal composition for treating leucopenia after chemotherapy

Country Status (1)

Country Link
CN (1) CN105521100A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108815301A (en) * 2018-07-02 2018-11-16 西安巨子生物基因技术股份有限公司 Has effects that composition of leukocytosis promoting and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108815301A (en) * 2018-07-02 2018-11-16 西安巨子生物基因技术股份有限公司 Has effects that composition of leukocytosis promoting and preparation method thereof

Similar Documents

Publication Publication Date Title
CN102988821B (en) Chinese medicine composition for treating carcinomatosis postoperation, postchemotherapy and postradiotherapy and preparation method of Chinese medicine composition
CN102772671B (en) Traditional Chinese medicine composition for treating deficiency of both qi and yin of sicca syndrome
CN101711848B (en) Chinese medicinal composition capable of adjunctively treating tumour
CN104257883A (en) Traditional Chinese medicine composition for treating leucopenia after chemotherapy
CN104436145A (en) Pharmaceutical composition for preventing and/or treating allergic rhinitis and allergic asthma
CN105521100A (en) Traditional Chinese medicinal composition for treating leucopenia after chemotherapy
CN103301353A (en) Pharmaceutical composition for treating atrophic vaginitis
CN105616633A (en) Preparation method of traditional Chinese medicine composition for treating leukopenia after chemotherapy
CN104983759A (en) Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof
CN104825817A (en) Traditional Chinese medicine preparation with antitumor effect
CN104840902A (en) Traditional Chinese medicine preparation for treating ovarian tumor
CN104825922A (en) Traditional Chinese medicine composition with anti-colorectal cancer activity and preparation method and application of traditional Chinese medicine composition
CN103341092A (en) Preparation method of powder for treating atrophic vaginitis
CN103301373A (en) Pharmaceutical composition for treating postpartum perineal mucosal lesions
CN101675961B (en) A medicinal preparation for treating breast cancer and preparation method thereof
CN103961506A (en) Traditional Chinese medicine composition as traditional Chinese medicine regulatory human body cellular immunity agonist
CN105616961A (en) Cancer chemoradiotherapy adjuvant-therapy traditional Chinese medicine and preparation method thereof
CN102462730B (en) Traditional Chinese medicine composition for treating tumors
CN104825980A (en) Traditional Chinese medicine preparation for treating diarrhea
CN110101820B (en) A Chinese medicinal composition for treating obesity
CN104587297A (en) Traditional Chinese medicine capsule for treating scleroderma and preparation method thereof
CN104189314A (en) Pharmaceutical composition for treating hyperlipidemia with phlegm and turbid repression syndrome
CN103211949B (en) Traditional Chinese medicine composition for treating gastric diseases of human body as well as preparation method and application thereof
CN103301374A (en) Pharmaceutical composition for treating postpartum non-specificity vaginitis
CN107913382A (en) A kind of Chinese and Western medicine composite preparation for treating hypertension-induced apoplexy and preparation method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160427